Per the company, thrombus formation can block blood flow through a catheter, thus preventing adequate dialysis treatment.ĪngioDynamics’ BioSentry Biopsy Tract Sealant System, designed specifically to reduce the incidence of biopsy-related pneumothorax (collapsed lung), is expected to complement Merit Medical’s comprehensive biopsy portfolio. Merit Medical’s acquired dialysis catheter portfolio includes the BioFlo DuraMax Dialysis Catheter with Endexo Technology, a proprietary material more resistant to thrombus (blood clot) accumulation, in vitro, unlike conventional non-coated dialysis catheters. These latest buyouts are a significant stepping stone for Merit Medical toward solidifying its foothold in the global dialysis space. Management believes that these acquisitions will likely strengthen its position in the dialysis and biopsy markets, besides expanding its growing specialty dialysis device offering (which includes WRAPSODY Cell-Impermeable Endoprosthesis, HeRO Graft and the Surfacer System devices).
This follows Merit Medical’s recent acquisition of the Surfacer Inside-Out Access Catheter System from Bluegrass Vascular Technologies, Inc.
#Suite life of zack free
( MMSI Quick Quote MMSI - Free Report) completed the acquisition of a portfolio of dialysis catheter products and the BioSentry Biopsy Tract Sealant System from AngioDynamics, Inc.
0 kommentar(er)
